Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prognostic Value of Adipokine Levels of Patients With Chronic Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02812797
Recruitment Status : Completed
First Posted : June 24, 2016
Last Update Posted : March 4, 2020
Sponsor:
Information provided by (Responsible Party):
Dongying Zhang, Chongqing Medical University

Brief Summary:
The purpose of this study is to determine whether expressions of adipokines can provide prognostic information concerning patients with chronic heart failure.

Condition or disease
Chronic Heart Failure

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 98 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 1 Year
Official Title: Prognostic Value of Adipokine Levels of Patients With Chronic Heart Failure
Actual Study Start Date : June 2016
Actual Primary Completion Date : August 2019
Actual Study Completion Date : January 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure




Primary Outcome Measures :
  1. All-cause mortality [ Time Frame: Change from Baseline at 3, 6 and 12 months ]

Secondary Outcome Measures :
  1. New York Heart Association (NYHA) Classification [ Time Frame: Week:4 ]
  2. re-hospitalization [ Time Frame: Change from Baseline at 3, 6 and 12 months ]
    Heart failure with re-hospitalization is documented by at least one of the following: worse exercise tolerance and respiratory distress with NYHA class III or IV symptoms, presence of pulmonary rales, or chest radiography showing pulmonary congestion, which needs an augmented decongestive regimen with oral or intravenous medications during an in-hospital stay.

  3. plasma brain natriuretic peptide (BNP) concentration [ Time Frame: Week:4 ]
  4. Cardiovascular death [ Time Frame: Change from Baseline at 3, 6 and 12 months ]
  5. Cardiac transplantation [ Time Frame: Change from Baseline at 3, 6 and 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients With Chronic Heart Failure
Criteria

Inclusion Criteria:

  • Patients who are giving open chest surgical treatment with a history of chronic heart failure (NYHA II ~ IV) more than 6 months.
  • Patients from whom informed consent has been properly obtained in writing prior to start of the trial.

Exclusion Criteria:

  • Patients with concurrent infection or any documented inflammatory illness, such as arthritis or connective tissue diseases,or any other malignancy.
  • Patients with a history of cardiomyopathy.
  • Patients with Chronic arrhythmia.
  • Pregnant women
  • Severe hepatic dysfunction or End-stage renal failure.
  • Uncontrolled hypertension.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02812797


Locations
Layout table for location information
China, Chongqing
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing, China, 400000
Sponsors and Collaborators
Chongqing Medical University
Investigators
Layout table for investigator information
Study Director: Dongying Zhang, doctor Chongqing Medical University
Additional Information:

Layout table for additonal information
Responsible Party: Dongying Zhang, Dr, Chongqing Medical University
ClinicalTrials.gov Identifier: NCT02812797    
Other Study ID Numbers: 2016-38-2
First Posted: June 24, 2016    Key Record Dates
Last Update Posted: March 4, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Dongying Zhang, Chongqing Medical University:
Adipokines
Chronic Heart Failure
Prognosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases